Erratum to: PRISM II: An open-label study to assess effectiveness of dextromethorphan/quinidine for pseudobulbar affect in patients with dementia, stroke or traumatic brain injury [BMC Neurol., 16 (2016) 89], DOI:10.1186/s12883-016-0609-0

Flora M. Hammond, David N. Alexander, Andrew J. Cutler, Stephen D'Amico, Rachelle S. Doody, William Sauve, Richard D. Zorowitz, Charles S. Davis, Paul Shin, Fred Ledon, Charles Yonan, Andrea E. Formella, Joao Siffert

Research output: Contribution to journalComment/debate

2 Scopus citations

Abstract

After publication of the original article [1], the authors noticed that there were errors in the caption of Fig. 3, and the y-axis of Fig. 6 itself. The following statement should not have been included in the caption of Fig. 3: "CNS-LS scores were not normalized." The CNS-LS is a rank-order scale, and is not normalized. This statement was included erroneously and the authors intended on removing it prior to resubmission, but this was unfortunately overlooked. Similarly, the y-axis within Fig. 6 was mislabelled. The CNS-LS scale ranges from 7 to 35, so the y-axis for Fig. 6 should start at a base score of 7 and not zero. The correct and updated version of Fig. 6, in which the data presented remain accurate and are unchanged, is published in this erratum.

Original languageEnglish (US)
Article number160
JournalBMC Neurology
Volume16
Issue number1
DOIs
StatePublished - Sep 2 2016

ASJC Scopus subject areas

  • Clinical Neurology

Fingerprint Dive into the research topics of 'Erratum to: PRISM II: An open-label study to assess effectiveness of dextromethorphan/quinidine for pseudobulbar affect in patients with dementia, stroke or traumatic brain injury [BMC Neurol., 16 (2016) 89], DOI:10.1186/s12883-016-0609-0'. Together they form a unique fingerprint.

  • Cite this